Latest news with #infliximab
Korea Herald
28-05-2025
- Business
- Korea Herald
Celltrion's Remsima SC hits fivefold growth in Europe
South Korean biopharmaceutical firm Celltrion announced Wednesday that the market share of Remsima SC, the subcutaneous formulation of the autoimmune disease treatment infliximab, has quintupled across Europe over just four years. According to the company, citing global pharmaceutical market research firm IQVIA, Remsima SC captured a 22 percent market share as of last year, surging from 4 percent in 2021 following its debut in 2020. When combined with the share of Remsima, the intravenous version, Celltrion's Remsima product line commanded a 71 percent market share in Europe. Celltrion noted that Remsima SC's success in Europe bodes well for the US market, given that its recent inclusion of Zymfentra — another brand name for Remsima SC in the US — in major US insurance formularies is expected to drive accelerated adoption. Celltrion's other autoimmune treatments are also making significant inroads in Europe. Yuflyma, its adalimumab-aaty biosimilar, secured a 21 percent market share last year. Meanwhile, its ustekinumab biosimilar, Steqeyma, launched in Europe in October, captured more than 2 percent market share within just a few months. 'Remsima SC's growing presence in Europe can be attributed to its convenience, treatment efficacy and tailored sales strategies from our local subsidiaries,' a Celltrion official said. 'With our existing products leading prescriptions in Europe, we plan to continue our growth through the launch of new biosimilars during the remainder of the year.'
BBC News
17-05-2025
- Health
- BBC News
Oxford patients with sarcoidosis in lungs given new drug
The first new drug approved for 50 years to treat a rare condition that creates swollen tissue on the lungs has been administered to Hunter became the first person with pulmonary sarcoidosis to receive infliximab as part of her treatment for the condition at the John Radcliffe Hospital in Oxford. Infliximab is currently used to treat inflammatory conditions, such as Crohn's disease, and has now been commissioned by the NHS for use in pulmonary condition causes granulomas - lumps made up of clusters of cells involved in inflammation - to develop in organs, and most commonly affects the lungs. Sarcoidosis can affect people of all ages and can be particularly severe in some cases - with patients often requiring multiple immunosuppressants to treat the affects about 1 in 10,000 people in the UK, according the charity Sarcoidosis well as the lungs it can also affect the skin, eyes, joints, nervous system, heart and other parts of the of pulmonary sarcoidosis include shortness of breath and a persistent dry cough, according to the NHS. Infliximab reduces the need for patients to rely on immunosuppressants - which can increase the risk of infections and further complications - by targeting a protein produced by overactive immune Hunter said she was "excited about the possibility of reducing the number of medications I need"."I have been on various immunosuppressants for a long time, and the side effects have started to surface," she said."The commissioning of this drug is very welcome news."Prof Ling-Pei Ho, who is a consultant in respiratory medicine at Oxford University Hospitals (OUH), was involved in the work that led to the drug's commissioning."We are very pleased to be able to offer a new medicine for our patients with severe lung sarcoidosis," she medical officer at OUH Prof Andrew Brent said that the new drug was "fantastic news" for patients."The commissioning of this drug is a great example of our teams' dedication to continually improving patient care," he added. You can follow BBC Oxfordshire on Facebook, X (Twitter), or Instagram.
